Raymond James Financial
SGMT icon

Raymond James Financial’s Sagimet Biosciences SGMT Stock Holding History

Raymond James Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57M Buy
332,023
+14,473
+5% +$98.4K ﹤0.01% 3307
2026
Q1 		$1.66M Buy
317,550
+31,300
+11% +$174K ﹤0.01% 3488
2025
Q4 		$1.69M Buy
286,250
+8,004
+3% +$57.5K ﹤0.01% 3398
2025
Q3 		$1.91M Buy
278,246
+13,571
+5% +$110K ﹤0.01% 3207
2025
Q2 		$2.02M Sell
264,675
-81,511
-24% -$344K ﹤0.01% 3079
2025
Q1 		$1.13M Buy
+346,186
New +$1.45M ﹤0.01% 3398

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Raymond James Financial's SGMT Position: Q2 2026 in Review

Raymond James Financial increased its Sagimet Biosciences (SGMT) stake by 4.6% in Q2 2026, buying an estimated $98.4K and bringing the position to 332,023 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3307.

Raymond James Financial first reported a position in SGMT in Q1 2025 and has held it in 6 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Raymond James Financial held 332,023 shares of Sagimet Biosciences worth $2.57M as of Q2 2026.
  • Raymond James Financial bought 14,473 Sagimet Biosciences shares in Q2 2026, an estimated $98.4K.
  • Sagimet Biosciences made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3307 holding.
  • Raymond James Financial first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.